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Background: There has been uncertainty regarding the benefit of glycemic control with antidiabetic agents in
prevention of diabetic macrovascular disease. Further development of novel antidiabetic agents is essential for
overcoming the burden of diabetic macrovascular disease. The renal sodium glucose co-transporter 2 (SGLT2)
inhibitor is a novel antihyperglycemic agent for treatment of type 2 diabetes. This work was performed to
determine whether empagliflozin, a novel SGLT2 inhibitor, can ameliorate cardiovascular injury and cognitive
decline in db/db mouse, a model of obesity and type 2 diabetes.
Methods: (1) Short-term experiment: The first experiment was performed to examine the effect of 7 days of
empagliflozin treatment on urinary glucose excretion and urinary electrolyte excretion in db/db mice. (2) Long-term
experiment: The second experiment was undertaken to examine the effect of 10 weeks of empagliflozin treatment
on cardiovascular injury, vascular dysfunction, cognitive decline, and renal injury in db/db mice.
Results: (1) Short-term experiment: Empagliflozin administration significantly increased urinary glucose excretion,
urine volume, and urinary sodium excretion in db/db mice on day 1, but did not increase these parameters from
day 2. However, blood glucose levels in db/db mice were continuously decreased by empagliflozin throughout
7 days of the treatment. (2) Long-term experiment: Empagliflozin treatment caused sustained decrease in blood
glucose in db/db mice throughout 10 weeks of the treatment and significantly slowed the progression of type 2
diabetes. Empagliflozin significantly ameliorated cardiac interstitial fibrosis, pericoronary arterial fibrosis, coronary
arterial thickening, cardiac macrophage infiltration, and the impairment of vascular dilating function in db/db mice,
and these beneficial effects of empagliflozin were associated with attenuation of oxidative stress in cardiovascular
tissue of db/db mice. Furthermore, empagliflozin significantly prevented the impairment of cognitive function in
db/db mice, which was associated with the attenuation of cerebral oxidative stress and the increase in cerebral
brain-derived neurotrophic factor. Empagliflozin ameliorated albuminuria, and glomerular injury in db/db mice.
Conclusions: Glycemic control with empagliflozin significantly ameliorated cardiovascular injury and remodeling,
vascular dysfunction, and cognitive decline in obese and type 2 diabetic mice. Thus, empagliflozin seems to be
potentially a promising therapeutic agent for diabetic macrovascular disease and cognitive decline.
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Type 2 diabetes is a major risk factor for cardiovascular
disease and cardiovascular disease is the leading cause of
mortality in patients with diabetes [1,2]. Previous large
clinical trials have established that strict glycemic control
significantly reduces diabetic microvascular complications
such as nephropathy or retinopathy [3-5]. On the other
hand, to date there has been uncertainty regarding
whether any current antihyperglycemic agents can actually
reduce cardiovascular event, because most of previous
clinical trials indicated no benefit of current antihypergly-
cemic agents in prevention of cardiovascular disease [3-8].
Moreover, diabetes is a major risk factor for cognitive
decline as well as cardiovascular disease [9-11]. However,
no information is available regarding the effect of anti-
hyperglycemic agents on cognitive decline in diabetes.
Hence, further development of other novel pharmaco-
logical approaches of glycemic control is necessary to
reduce macrovascular disease and cognitive impairment
in patients with diabetes.
The kidney plays a key role in glucose homeostasis
and has recently become a target organ for treatment of
diabetes. Under normal conditions, the kidney reabsorbs
all the glucose from the glomerular filtrate and back into
the blood. Sodium glucose co-transporter 2 (SGLT2) is
located in the brush border membrane of the proximal
convoluted tubule of the nephron, and mediates the
majority of glucose reabsorption from glomerular filtrate
[12,13]. Pharmacological inhibition of SGLT2 increases
urinary glucose excretion (UGE) and consequently de-
creases blood glucose levels in an insulin-independent
manner [12,13]. Thus, SGLT2 inhibitors represent a novel
class of antihyperglycemic drugs and have recently
become available for treatment of patients with type 2
diabetes [12-15]. It is a future clinical key issue whether
SGLT2 inhibitor can prevent macrovascular complication,
cognitive decline, or microvascular complication in dia-
betic patients. Previous preclinical studies using diabetic
animal models support the notion that SGLT2 inhibitors
may exert protective effects against diabetic nephropathy
(diabetic microvascular disease) [16-21]. However, to the
best of our knowledge, the effect of SGLT2 inhibition on
cardiovascular disease and cognitive function in diabetes
remains to be explored.
Empagliflozin [22-24] is a novel inhibitor of SGLT2,
and is characterized by highly selective and potent inhibi-
tor of SGLT2, compared with other SGLT2 inhibitors. In
the present experimental study, we hypothesized that
glycemic control with empagliflozin can ameliorate
cardiovascular injury and cognitive decline in obese and
type 2 diabetic mice. To demonstrate our hypothesis, we
examined the effects of long-term empagliflozin treatment
on cardiac fibrosis and inflammation, coronary arterial
remodeling, vascular dysfunction, cardiovascular oxidativestress, and learning and reference/working memory in
db/db mice, a useful model of obesity and type 2 diabetes.
We obtained the evidence that empagliflozin may be a
promising therapeutic agent for diabetic macrovascular
disease and cognitive decline.
Methods
Animals
All procedures were performed in accordance with insti-
tutional guidelines for animal research and were approved
by the Animal Care and Use Committee of Kumamoto
University. Male db/db mice (C57BLKS/J-leprdb/leprdb)
and male nondiabetic and lean db/m mice (C57BLKS/J-
leprdb/+) as control were purchased from Japan Charles
River Laboratories Japan Inc. (Yokohama, Japan). All ani-
mals were housed in an animal facility with a 12-hour
light-dark cycle and were given the standard chow and
water ad libitum.
Drugs
Empagliflozin [22-24], a selective sodium glucose cotran-
sporter-2 (SGLT2) inhibitor, was kindly gifted from
Boehringer Ingelheim Pharma GmbH & Co.KG, Germany.
Experiment I: Effect of short-term (7 days) empagliflozin
administration
The main objective of Experiment I was to investigate
the effect of short-term (7 days) empagliflozin treatment
on urinary glucose excretion, urine volume, urinary elec-
trolytes, and blood glucose. db/db mice at 7 weeks of
age already displayed significant obesity and type 2 dia-
betes. Therefore, in this study, drug treatment of db/db
mice was initiated from 7 weeks of age. db/db mice were
acclimatized to the metabolic cages to collect 24-hour
urine samples every day from 5 days before the experi-
ment, randomly assigned 2 groups, and were given (1)
the standard diet (MF diet, ORIENTAL YEAST Co., Ltd,
Tokyo, Japan) (2) the standard diet containing 0.03%
empagliflozin for 7 days and 24-hour urine samples were
collected from each mouse every day. Non fasting blood
glucose was measured before and 1, 3, and 7 days after
start of empagliflozin administration.
Furthermore, the effect of short-term empagliflozin
treatment was also examined in non-diabetic db/m mice
in the same manner as the above mentioned experiment
on db/db mice.
Experiment II: Effect of long-term (10 weeks) empagliflozin
administration on cardiovascular complications, cognitive
function, and renal injury
Experiment II was performed to mainly investigate the
effects of long term empagliflozin treatment on cardiovas-
cular injury, vascular dysfunction, cognitive dysfunction,
and renal injury. Seven-week-old db/db mice were assigned
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diet, ORIENTAL YEAST Co., Ltd, Tokyo, Japan) or (2)
the standard diet containing 0.03% empagliflozin in the
same manner as the Experiment I, and drug treatment
was performed for 10 weeks. The design of the Experi-
ment II is shown in Figure 1. Body weight and blood
glucose were periodically measured every week through-
out the treatment. Blood samples were collected from the
tail vein of mice for measurement of non-fasting blood
glucose. Blood pressure (BP) was measured at 3 and 8
weeks after the start of drug treatment. After 4 and 8
weeks of drug treatment, mice were housed in metabolic
cages to collect 24-hour urine for measurement of urinary
glucose, urinary electrolytes, urinary albumin, and urinary
creatinine excretions. Oral glucose tolerance test was per-
formed after 7 weeks of drug treatment. Morris water
maze test (MWM) was performed at 9 weeks of drug
treatment. At the end of 10 weeks of treatment, 17-week-
old db/db mice were anaesthetized with isoflurane, the
blood was collected by cardiac puncture, to measure serum
insulin and glucose. The heart, thoracic aorta and kidney
were rapidly excised to perform histological and biochem-
ical examinations, as described below in detail.
Experiment III: Effect of empagliflozin administration on
cerebral oxidative stresss and brain-derived neurotrophic
factor of db/db mice
To examine the effect of empagliflozin on cerebral oxida-
tive stress and brain-derived neurotrophic factor (BDNF)
in db/db mice, empagliflozin treatment was performed on
db/db mice for 16 days in the same manner as the above
experiment, and cerebral tissue was collected from each
mouse by the modification of our previous method [25].
Measurement of blood pressure
Blood pressure was measured by tail-cuff plethysmography
(BP-98A; Softron Co, Tokyo, Japan).0
BG
Empagliflozin tr






Figure 1 The design of Experiment II. Abbreviations used: BG, measurem
glucose tolerance test; MWM, Moris water maze test.Oral glucose tolerance test
Mice were deprived of food for overnight and then orally
given glucose (1 mg/g body weight). Tail vein bloods
were taken from mice at 0, 30, 60 and 120 min after glu-
cose administration to measure serum glucose concentra-
tions. Blood glucose concentrations were measured by a
portable glucose meter (Sanwa Kagaku Kenkyusho CO.,
LTD, Nagoya, Japan).
Vessel ring preparation and organ chamber experiments
Isometric tension studies were performed, as previously
described [26]. In brief, thoracic aortas from mice were
cut into 5 mm rings, and mounted in organ baths filled
with modified Tyrode buffer (pH 7.4; NaCl 121 mmol/l,
KCl 5.9 mmol/l, CaCl2 2.5 mmol/l, MgCl2 1.2 mmol/l,
NaH2PO4 1.2 mmol/l, NaHCO3 15.5 mmol/l, and D
(+)-glucose 11.5 mmol/l) aerated with 95% O2 and 5%
CO2 at 37
°C. The preparations were attached to a force
transducer, and isometric tension was recorded on a poly-
graph. A resting tension of 1 g was maintained throughout
the experiment. Vessel rings were precontracted with
L-phenylephrine (10−7 mol/l). After the plateau was
attained, the rings were exposed to increasing concentra-
tions of acetylcholine (10−9 mol/l to 10−4 mol/l) or S-
nitroso-N-acetylpenicillamine (SNAP) (10−9 mol/l to 10−4
mol/l) to obtain cumulative concentration-response curves.
Measurement of tissue superoxide
Heart, aorta, kidney, and brain removed from mice, were
immediately frozen in Tissue-Tek O.C.T. embedding
medium (Sakura Finetek, Tokyo, Japan). Dihydroethidium
(DHE) was used to evaluate tissue superoxide levels in
situ, as described [27]. DHE fluorescence of each tissue
section was quantified by Lumina Vision version 2.2
(Mitani corporation, Tokyo, Japan). The mean fluores-
cence was quantified and expressed relative to values
obtained from control mice.10 wk
eatment










ent of blood glucose; BP, measurement of blood pressure; OGTT, oral
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(8-OHdG)
For measurement of cerebral 8-OHdG, cerebral DNA
was extracted with DNA Extractor TIS kit (Wako Pure
Chemical Industries, Ltd. Osaka, Japan) and cerebral
8-OHdG was measured by New 8-OHdG Check ELISA
(Japan Institute for the Control of Aging, NIKKEN
SEIL CO., Ltd. Tokyo, Japan).
Histological and immunohistochemical analysis
Hearts were fixed in 4% (wt/vol.) paraformaldehyde,
embedded in paraffin, sectioned 5-μm slices, and stained
with Sirius Red F3BA (0.5% wt/vol. in saturated aqueous
picric acid; Aldrich Chemical Company, St Louis, MO,
USA) for the measurement of cardiac interstitial fibrosis,
pericoronary arterial fibrosis and coronary arterial thick-
ness. The area of fibrosis and coronary arterial thickness
was analyzed by Lumina Vision version 2.2 (Mitani
corporation, Tokyo, Japan). Kidneys were fixed in 4%
























































Figure 2 Effects of short-term (7 days) empagliflozin administration o
(B), 24 hr-urine volume (C) and 24 hr-urinary sodium excretion (D) in
with metabolic cages every day before and throughout the experiment. Ab
(untreated) db/db mice; Empa, empagliflozin-treated db/db mice; pre, the
control db/db mice. Values are mean ± SEM (n = 10-11).slices, and stained with periodic acid-Schiff (PAS).
Glomerular sclerosis was assessed in PAS stained kidney
sections by a semiquantitative score (grades 0 to +4), as
previously described [28]. Fifty glomeruli were randomly
selected from each mouse to perform the analysis.
For detection of cardiac and glomerular macrophage
infiltration, frozen cardiac and kidney sections were incu-
bated overnight with the primary antibody(rat anti-mouse
CD68, Serotec; ×1000) followed by anti-rat secondary
antibody (BioSource, Camarillo, CA, USA), as described
previously [28].
Morris water maze test
Learning and reference/working memory were evaluated
by the Morris water maze (MWM) test, as previously
described [29]. Groups were blinded to the examiners.
In brief, swimming paths were video-tracked with a
camera fixed on the ceiling of the room and analyzed by
the software (Muromachi Kikai, Tokyo, Japan). A train-

















































n non-fasting blood glucose (A), 24 hr-urinary glucose excretion
db/db mice. Twenty four-hour urine of each mouse was collected
breviations used: UGE, urinary glucose excretion; control, control
data obtained before start of drug treatment. *p < 0.05, †p < 0.01 vs
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and guided to climb onto the hidden platform and
allowed to remain there for 30 seconds before returning
to their cages. On the hidden platform test, the mice had
5 sessions at 20-minute intervals per day on the following
4 consecutive days (day 1 to 4). During each session mice
were released from randomly assigned 3 starting points
and swam for 100 seconds. On the probe test at day 5, the
hidden platform was removed and the mice swam freely
for 100 seconds. The number of times the mice crossed
the original platform location was recorded. On the visible
platform test which was performed after the probe test on
day 5, the platform was elevated 5 cm above the water sur-
face level and placed in a different position. The mice were
given four sessions of a visible trial with an inter-session
interval of 20 minutes.
Western blot analysis
Western blot analysis of cerebral tissue protein was
performed by our previous method described [30]. Anti-















































Figure 3 Effects of short-term (7 days) empagliflozin administration o
db/db mice. Abbreviations used are the same as in Figure 2. *p < 0.05, †p(x2000, Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA), anti-p67phox (67kDa) (x5000, BD Biosciences, San
Jose, CA, USA), anti-BDNF (14kDa) (x2000, Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA), anti-GAPDH
(37kDa) (x5000, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA). The intensity of the bands was quantified
using NIH Image analysis software v1.61. In individual
samples, each value was corrected for that of GAPDH.
Analysis of biochemistry
Serum insulin levels were quantified by using a commercial
ELISA kit (Morinaga, Tokyo, Japan). Urine biochemistry
were performed at SRL Inc (Tokyo, Japan).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 5.02 for Windows (GraphPad Software Inc., San
Diego, CA) and Ekuseru-Tokei 2012 statistical software
(Social Survey Research Information Co, Ltd, Tokyo, Japan).
Data were presented as mean ± SEM. The data on time
course experiments were analyzed by two-way ANOVA(B)



















n body weight gain (A), food intake (B) and water intake(C) of
< 0.01 vs control db/db mice. Values are mean ± SEM (n = 10-11).
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test for multiple comparisons. Statistical significance was
determined with one-way ANOVA, followed by the
Newman–Keuls post hoc test between each group. Data
were analyzed with the Kruskal-Wallis test followed by
Steel-Dwass post hoc test, when similar variances were
not obtained among comparison groups or a normal
distribution was not confirmed among comparison groups.
In all tests, differences were considered statistically signifi-
cant at a value of P < 0.05.
Results
The effects of short-term (7 days) empagliflozin treatment
on blood glucose, urinary parameters and body weight of
db/db mice and non-diabetic db/m mice
Figure 2 shows the time course of non-fasting blood
glucose, 24-hr urinary glucose excretion, 24-hr urine
volume and 24-hr urinary sodium excretion in control
and empagliflozin-treated db/db mice. Non-fasting blood
glucose of db/db mice was already significantly reduced































































































Figure 4 Effects of short-term (7 days) empagliflozin administration o
(B), 24 hr-urine volume (C), 24 hr-urinary sodium excretion (D), body
insulin level (H) of db/m mice. Abbreviations: db/m, non-diabetic db/m m
db/m mice. *p < 0.05, †p < 0.01, vs control db/m mice. Values are mean ± SEMremained significantly decreased throughout 7 days of the
treatment (Figure 2 (A)). Only on day 1, 24-hr urinary
glucose excretion, urine volume and urinary sodium
excretion (in Figure 2 (B), (C), and (D), respectively)
were significantly increased in db/db mice given empa-
gliflozin, but these parameters did not differ between
empagliflozin and control groups from day 2.
As shown in Figure 3(A), body weight gain of empagli-
flozin group was less than that of control group on day
1-5 (except for day 3) after start of the treatment, but
there was no significant difference in body weight gain
between the groups on day 6 and 7. As shown in Figure 3
(B), empagliflozin treatment did not affect food intake
compared with control throughout the treatment. Water
intake of db/db mice was significantly increased by
empagliflozin only day 1 (Figure 3(C)).
We also examined the effect of short-term empagliflo-
zin treatment in non-diabetic db/m mice. As shown in
Figure 4, empagliflozin treatment significantly increased
24-hr urinary glucose excretion, urine volume, sodium
excretion, and water intake, and significantly lessened(C) (D)































































































n non-fasting blood glucose (A), 24 hr-urinary glucose excretion
weight gain (E), food intake (F), water intake (G), and serum
ice; Control, control (untreated) db/m mice; Empa, empagliflozin-treated
(n = 10).
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However, at the end of drug treatment (after 7 days of
treatment), relative to control, empagliflozin did not
significantly alter blood glucose levels (93.5 ± 3.2 mg/dl vs
84.7 ± 4.0 mg/dl) or serum insulin levels (2.92 ± 0.03 vs
2.99 ± 0.03 (ng/ml)) in db/m mice.
The effects of long-term (10 weeks) empagliflozin treatment
on hyperglycemia, serum insulin, body weight, urinary
parameters, and blood pressure of db/db mice
As shown in Figure 5(A), non-fasting blood glucose
levels of db/db mice were much less in empagliflozin-
treated group than in control group throughout 10
weeks of the treatment. Oral glucose tolerance test in
Figure 5(B) indicates that empagliflozin improved glu-
cose tolerance in db/db mice to almost similar levels to
nondiabetic db/m mice. As shown in Figure 5(C),
serum insulin levels were not different between db/m
mice and control (untreated) db/db mice at the end of
10 weeks of the treatment (at the age of 17 weeks).
However, serum insulin levels in empagliflozin-treated
db/db mice were higher than those in control db/db
mice (p < 0.05) (Figure 5(C)). Body weight of db/db mice
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Figure 5 Effects of long-term (10 weeks) empagliflozin administration
serum insulin levels (C), and body weight (D) of db/db mice. Abbrevia
db/db mice; Empa, empagliflozin-treated db/db mice. *p < 0.05, †p < 0.01,larger than those of control db/db mice after 7 weeks
of the treatment (Figure 5(D)).
Figure 6(A)-(E) indicate the data obtained from 24-hour
urine samples collected with metabolic cages at 4 and 8
weeks after start of empagliflozin treatment. Urinary
glucose excretion and urine volume (Figure 6 (A) and (B),
respectively) were significantly smaller in empagliflozin
group than in control group. There was no significant
difference in urinary sodium excretion (Figure 6 (C)),
food intake (Figure 6 (D)) or water intake (Figure 6 (E))
between empagliflozin-treated and control db/db mice,
except for the significant decrease in water intake in
empagliflozin group at 4 weeks.
Figure 6(F) shows blood pressure at 3 and 8 weeks after
start of the treatment. Blood pressure was comparable
between control and empagliflozin-treated db/db mice.
Effects of empagliflozin on cardiac injuries in db/db mice
Figure 7 indicates that cardiac interstitial fibrosis, peri-
coronary arterial fibrosis, coronary arterial thickening,
cardiac interstitial macrophage infiltration, and cardiac
superoxide were significantly greater in db/db mice than
in db/m mice. Ten weeks of empagliflozin treatment sig-
nificantly ameliorated cardiac interstitial fibrosis (p < 0.05),(D)





















































on non-fasting blood glucose (A), oral glucose tolerance test (B),
tions: db/m, non-diabetic db/m mice; Control, control (untreated)






















































































































































Figure 6 Effects of long-term empagliflozin administration on urinary glucose excretion (UGE) (A), urine volume (B), urinary sodium
excretion (C), food intake (D), water intake (E), and blood pressure (F) of db/db mice. Abbreviations used are the same as in Figure 5.
*p < 0.05, †p < 0.01 vs control db/db mice. Values are mean ± SEM (n = 9-11).
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thickening (P < 0.05), cardiac interstitial macrophage infil-
tration (p < 0.01), and cardiac superoxide levels (p < 0.01)
in db/db mice.
Effects of empagliflozin on vascular dilating function and
aortic superoxide in db/db mice
As shown in Figure 8(A), vascular endothelium-dependent
relaxation by acetylcholine in db/db mice was significantly
impaired compared with nondiabetic db/m mice. Treat-
ment with empagliflozin significantly ameliorated the im-
pairment of vascular endothelial function compared with
control db/db mice. Vascular endothelium-independent
relaxation by S–nitroso–N-acetylpenicillamine (SNAP) was
slightly but significantly impaired in db/db mice compared
with db/m mice, and empagliflozin partially ameliorated
the impairment of SNAP-induced vascular relaxation
(Figure 8 (B)). As shown in Figure 8(C), aortic superoxide
levels were significantly greater in db/db mice than db/m
mice (p < 0.01). Empagliflozin significantly reduced aortic
superoxide in db/db mice (p < 0.01).
Effects of empagliflozin on cognitive function of db/db mice
As shown by the Morris water maze test in Figure 9,
16-week-old db/db mice showed significantly impairedlearning and reference/working memory compared
with the age-matched db/m mice. Escape latency of the
hidden plat form test was greater in control db/db mice
than in nondiabetic db/m mice (p < 0.01), and empagliflo-
zin treatment significantly decreased the increased escape
latency in db/db mice (p < 0.01) (Figure 9 (A)). Number of
times across the platform in the probe test was smaller in
control db/db mice than in db/m mice (p < 0.01), and
empagliflozin reversed it in db/db mice (p < 0.01) (Figure 9
(B)). There was no difference between empagliflozin-
treated and control db/db mice regarding escape latency
in the visible test (Figure 9 (C)) or swimming speeds
(Figure 9 (D)).
Effects of empagliflozin on cerebral oxidative stress and
brain-derived neurotrophic factor of db/db mice
Empagliflozin treatment significantly ameliorated cerebral
superoxide (P < 0.01) (Figure 10 (A)-(C)) and 8-OHdG, a
marker of DNA oxidative damage (P < 0.01) (Figure 10
(D)) in db/db mice. The attenuation of cerebral oxidative
stress by empagliflozin was associated with the reduction
of cerebral NADPH oxidase subunits, gp91 (P < 0.05) and
p67 (P < 0.01) (Figure 10 (E)(F)). Moreover, empagliflozin
treatment significantly augmented cerebral BDNF levels

















































































































Figure 7 Effect of long-term empagliflozin treatment on cardiac interstitial fibrosis (A), peri-coronary arterial fibrosis and coronary arterial
thickening (B), cardiac macrophage infiltration (C) and cardiac superoxide (D) in db/db mice. Upper panels in (A) and (B) indicate representative
photomicrographs of cardiac sections stained with Sirius red. Upper panels in (C) and (D) indicate representative photomicrographs of cardiac sections
stained with CD68 antibody and dihydroethidium, respectively. Abbreviations used are the same as in Figure 5. *p < 0.05, †p< 0.01 vs control db/db mice.
Values are mean ± SEM (n = 9-11). Bar = 100 μm in (A), (C), and (D). Bar = 50 μm in (B).
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db/db mice exhibited higher ratio of urinary albumin to
creatinine excretions, higher glomerular sclerosis index,
greater glomerular macrophage infiltration, and larger
glomerular superoxide than nondiabetic db/m mice
(Figure 11). Treatment of db/db mice with empagliflo-
zin significantly ameliorated all these parameters related
to glomerular injury.
Discussion
Despite a number of therapeutic options, hyperglycemia
in diabetic patients is often poorly controlled. SGLT2 in-
hibitors represent a novel class of drugs for treatment of
type 2 diabetes and exert insulin-independent blood glu-
cose lowering effects through the inhibition of glucose
reabsorption and subsequent increase of urinary glucose
excretion [12-14]. Furthermore, SGLT2 inhibitors do notincrease the risk of hypoglycemia. Thus, SGLT2 inhibitors
are expected to be a novel and promising agent for
treatment of type 2 diabetes. Empagliflozin is a selective
inhibitor of SGLT2 with good safety profile and does not
require dose adjustments in patients with renal impair-
ment [31-34]. The major findings of this study was that
glycemic control with empagliflozin significantly amelio-
rated cardiac fibrosis and inflammation, coronary arterial
remodeling, vascular dysfunction, and cognitive impair-
ment in obese and type 2 diabetic mice. Furthermore,
these beneficial effects of empagliflozin on cardiovascular
injury and cognitive impairment were associated with the
significant attenuation of oxidative stress in cardiovascular
and cerebral tissues. These observations provide the
experimental evidence supporting that empagliflozin may
be a promising therapeutic agent for macrovascular com-
plications and cognitive decline in type 2 diabetes.










































































Figure 8 Effect of long-term empagliflozin treatment on vascular relaxation by acetylcholine (A) and by SNAP (B), and vascular
superoxide (C) in thoracic aortas of db/db mice. Upper panels in (C) are representative photomicrographs of dihydroethidium-stained
aortic section. Bar = 50 μm. Abbreviations used are the same as in Figure 5. *p < 0.05, †p < 0.01, vs control db/db mice. Values are
mean ± SEM (n = 9-11).
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in diabetic patients and the burden of cardiovascular
disease due to diabetes mellitus has gone on increasing
[1,2]. Although strict glycemic control is well established
to reduce diabetic microvascular complications such as
nephropathy or retinopathy, the benefit of glycemic con-
trol in preventing the macrovascular complications have
been difficult to establish and there have been conflict-
ing findings from previous large clinical trials [3-5,7].
Furthermore, dipeptidyl-peptidase IV inhibitors, a novel
class of antidiabetic agent, have been recently reported
to fail to improve cardiovascular outcomes in large
clinical trials [6,8,12-14]. A multiple lines of experimental
studies [17,20,21] on type 1 or type 2 diabetic animals
show that glycemic control with SGLT2 inhibitors reduces
the progression of diabetic nephropathy, one of the
major microvascular complications attributable to dia-
betes. However, to our knowledge, it remains to be deter-
mined whether the SGLT2 inhibitor can protect against
cardiovascular disease or cognitive impairment. Therefore,
in the present study, we examined the effect of empa-
gliflozin, a SGLT2 inhibitor, on cardiovascular injuryand cognitive function in db/db mice, a useful model
of obesity and type 2 diabetes.
In the present study, we obtained the evidence that
empagliflozin ameliorated cardiac fibrosis and inflamma-
tion, coronary arterial remodeling, and the impairment of
vascular dilating function in obese type 2 diabetic mice.
Accumulating evidence [35-37] establish that hyper-
glycemia enhances tissue oxidative stress which plays a
key role in the pathophysiology of diabetes mellitus and
its complications. Therefore, in this study, we examined
the effect of empagliflozin on cardiovascular oxidative
stress in db/db mice, and found that empagliflozin attenu-
ated the oxidative stress in cardiac and vascular tissues
of db/db mice. We have previously reported that direct
attenuation of oxidative stress in db/db mice with antioxidant
causes the amelioration of cardiovascular injury, thereby
demonstrating the direct involvement of oxidative stress
in the progression of cardiovascular injury in db/db mice
[28]. Taken together, our present observations support the
notion that the amelioration of cardiovascular injury by

































































































Figure 9 Effect of long-term empagliflozin treatment on cognitive function of db/db mice estimated by Morris water maze test.
Cognitive function was evaluated by Morris water maze test at 9 weeks after the treatment. (A) indicates escape latency of the hidden platform
test on 4 consecutive days (1-20 sessions). (B) indicates number of times across the platform in the probe test. (C) indicates escape latency in the
visible test. (D) indicates swimming speeds. Abbreviations used are the same as in Figure 5. Values are mean ± SEM (n = 9-11).
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http://www.cardiab.com/content/13/1/148Diabetes is one of the major risk factors responsible
for cognitive deficits such as Alzheimer’s disease and
vascular dementia [9-11]. However, the potential benefit
of anti-diabetic agents in prevention of cognitive deficits
is unknown. Previous studies [38-40] demonstrate that
db/db mice are characterized by impaired cognitive
performance, thereby being regarded as a useful model
to investigate cognitive decline attributable to diabetes.
Therefore, in this study, we investigated the effect of
empagliflozin on cognitive function in db/db mice. Of
note, empagliflozin significantly prevented the progression
of cognitive impairment (learning and reference/working
memory) in diabetic mice, as shown by the findings on
water maze test. To examine the potential mechanism
underlying the amelioration of cognitive impairment by
empagliflozin, we examined the effects of empagliflozin
on cerebral oxidative stress. We found that empagliflozin
treatment significantly attenuated cerebral oxidative stressand DNA oxidative damage in db/db mice, as shown by
the reduction of cerebral superoxide and 8-OHdG, and
this attenuation of cerebral oxidative stress was associated
with the reduction of cerebral NADPH oxidase subunits,
gp91phox and p67phox levels. Therefore, the improve-
ment of cognitive function by empagliflozin seems to be
attributed to the attenuation of oxidative stress. Moreover,
we also examined the effect of empagliflozin treatment on
cerebral BDNF, since BDNF [32], a key protein promoting
memory and survival of neurons, is significantly reduced
in diabetic patients and diabetic animals [31,41] including
db/db mice [42] and the decrease in cerebral BDNF is
shown to be associated with cognitive decline [41,43].
Interestingly, empagliflozin treatment significantly in-
creased cerebral BDNF levels in db/db mice. These
observations provided the evidence supporting that the
increase in BDNF as well as the attenuation of oxida-

























































































































Figure 10 Effect of empagliflozin treatment on cerebral superoxide ((A)-(C)), cerebral 8-hydroxy-deoxyguanosine (8-OHdG) (D),
gp91phox (E), p67phox (F), and brain-derived neurotrophic factor (BDNF)(G) of db/db mice. Upper panels in (A), (B), and (C) indicate
representative photomicrograph of DHE-stained cerebral sections (hippocampus, cortex, and white matter, respectively). Upper panels in (E), (F),
and (G) indicate representative Western blot band. Abbreviations used are the same as in Figure 1. Values are mean ± SEM (n = 11). *p < 0.05,
†p < 0.01, vs control db/db mice.
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http://www.cardiab.com/content/13/1/148of prevention of cognitive impairment by empagliflozin.
Thus, glycemic control with empagliflozin is proposed
to be potentially a promising strategy for prevention of
diabetes-induced cognitive deficits. However, future clin-
ical study is needed to define our proposal.
In this study, we also examined the effects of empa-
gliflozin on glomerular injury in db/db mice. We found
that empagliflozin exerts protective effects against diabetic
nephropathy, as shown by the reduction of urinary albu-
min excretion, glomerular sclerosis index, glomerular
macrophage infiltration, and glomerular superoxide in
db/db mice with empagliflozin. Our present results are
in good agreement with previous reports regarding
various SGLT2 inhibitors [17-19,41,44] including empagli-
flozin [16]. Thus, our present work confirms previous
experimental findings supporting the benefit of SGLT2
inhibitors in prevention of diabetic nephropathy.
High blood pressure as well as diabetes is a major risk
factor for cardiovascular disease and cognitive decline.Interestingly, clinical findings on type 2 diabetic patients
demonstrate that SGLT2 inhibitors including empagliflo-
zin significantly reduce blood pressure in diabetic patients
[13,15]. Therefore, in this study, we also measured blood
pressure in db/db mice. However, we found no significant
alteration of blood pressure in db/db mice treated with
empagliflozin. Thus, the protective effects of empagliflozin
against cardiovascular and glomerular injuries, and cogni-
tive impairment in db/db mice seems not to be attributed
to blood pressure.
Accumulating clinical data show that SGLT2 inhibitors
including empagliflozin reduces body weight in type 2
diabetic patients and glucose lowering action of SGLT2
inhibitors is insulin-independent [12-14,31]. In the long-
term experiment of the present study, serum insulin
levels were higher and the body weight was greater
in empagliflozin-treated db/db mice than in control
(untreated) db/db mice. However, it is unlikely that
































































































Figure 11 Effects of empagliflozin on urinary albumin/creatinine ratio (A), glomerular sclerosis (B), glomerular macrophage infiltration
(C) and glomerular superoxide (D) of db/db mice. Urinary albumin/creatinine ratio in (A) was measured at 4 and 8 weeks after start of drug
treatment. Upper panels in (B), (C), and (D) indicate representative photomicrographs of renal sections stained with PAS, CD68 antibody, and
dihydroethidium, respectively. Abbreviations used are the same as in Figure 5. *p < 0.05, †p < 0.01 vs control db/db mice. Values are mean ± SEM
(n = 9-11). Bar = 50 μm in (B), (C), and (D).
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http://www.cardiab.com/content/13/1/148empagliflozin-treated db/db mice is mediated by the
direct action of empagliflozin. Along with aging, db/db
mice are shown to exhibit the exhaustion of pancreatic
β-cells because of long-standing glucose toxicity attrib-
uted to severe hyperglycemia and subsequently exhibit
progressive decrease in serum insulin levels and loss of
body weight gain [26,28,44]. Taken together with the
findings that empagliflozin treatment substantially im-
proved hyperglycemia, the greater body weight and the
higher serum insulin levels in empagliflozin-treated
db/db mice than in control (untreated) db/db mice can
be explained by the significant prevention by empagli-
flozin of aging-associated decrease in serum insulin
levels and of aging-associated loss of body weight gain
in db/db mice.
The data on short-term (7 days) empagliflozin admin-
istration in db/db mice indicates that the significant
increase in 24-hour urinary glucose excretion on day 1
after start of empagliflozin treatment was accompanied
by not only the remarkable reduction of blood glucose
but also the significant and transient increase in urine
volume and urinary sodium excretion, and the signifi-
cant decrease in body weight gain. However, from day 2
after the treatment, despite the remarkable continuousreduction of blood glucose, empagliflozin did not increase
urinary glucose excretion, urine volume, and urinary so-
dium excretion in db/db mice, compared with control
(untreated db/db mice). Furthermore, in the experiment
on long-term empagliflozin treatment, urinary glucose
excretion and urine volume were lower in empagliflozin
group than in control group, although empagliflozin
group had continuously much less blood glucose levels
compared with control group. These paradoxical find-
ings are in good agreement with previous report [44],
and can be explained by the fact that the significant
reduction of blood glucose levels attributed to the in-
creased urinary glucose excretion with empagliflozin re-
sults in the significant decrease in the glucose content in
glomerular filtrate and subsequently leads to the decrease
in urinary glucose excretion.
Conclusions
In conclusion, glycemic control with empagliflozin ame-
liorated cardiac fibrosis and inflammation, coronary arter-
ial remodeling, vascular dysfunction, cognitive decline as
well as glomerular injury in obese type 2 diabetic mice,
thereby highlighting empagliflozin, a SGLT2 inhibitor, as
potentially a promising agent for prevention of diabetic
Lin et al. Cardiovascular Diabetology 2014, 13:148 Page 14 of 15
http://www.cardiab.com/content/13/1/148macrovascular disease and cognitive decline as well as
nephropathy. However, no sufficiently powered clinical
trial has yet elucidated the benefit of a SGLT2 inhibitor
in prevention of diabetic macrovascular and microvascular
complications, although large clinical trials to address this
issue are now on going [45].
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